高敏检测法提升AR-V7检出率并预测mCRPC对ARS抑制剂的耐药
该前瞻性研究纳入41例转移性去势抵抗性前列腺癌(mCRPC)患者,采用AdnaTest平台富集循环肿瘤细胞(CTC),比较高敏AR-V7检测(hsAR-V7)与常规检测的检出率及对雄激素受体信号(ARS)抑制剂疗效的预测能力。结果显示hsAR-V7将AR-V7检出率从22%提升至56%,且对PSA无进展生存(PFS)和影像学PFS的区分能力(C-index)优于常规检测,hsAR-V7+患者PSA应答率更低、PFS更短。
要点
- hsAR-V7检测将AR-V7检出率从22%提高至56%。
- hsAR-V7对PSA PFS的C-index为0.74,优于常规检测的0.60。
- hsAR-V7+患者PSA应答率53%,低于hsAR-V7-患者的93%(p=0.016)。
核心结论
- hsAR-V7检测在mCRPC中实现了最高的AR-V7检出率,且对长期临床结局的区分能力优于常规检测。
研究设计与样本
- 前瞻性研究,纳入41例mCRPC患者,使用AdnaTest平台富集CTC,分别以常规法和高敏法检测AR-V7。
主要发现
- hsAR-V7检出率56%,常规法22%。
- hsAR-V7对PSA PFS的C-index为0.74(95%CI 0.60-0.88),对影像学PFS为0.70(95%CI 0.55-0.85)。
- 常规AR-V7对PSA PFS的C-index为0.60(95%CI 0.51-0.72),对影像学PFS为0.56(95%CI 0.44-0.67)。
- hsAR-V7+患者PSA应答率53%,hsAR-V7-患者93%(p=0.016)。
- hsAR-V7+患者中位PSA PFS为3.0个月,hsAR-V7-患者未达到(p=0.0001);中位影像学PFS为6.0个月 vs 未达到(p=0.0026)。
临床怎么用
- hsAR-V7检测可更敏感地识别对阿比特龙或恩扎卢胺耐药的mCRPC患者,辅助治疗决策。
局限性
- 样本量较小(41例),需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In metastatic castration-resistant prostate cancer (mCRPC), androgen receptor splice variant 7 (AR-V7) expression is associated with a low response to androgen receptor signaling (ARS) inhibitors such as abiraterone or enzalutamide. OBJECTIVE: To perform a highly sensitive assay for detecting AR-V7 (hsAR-V7) in circulating tumor cells (CTCs) and evaluate its ability to predict response to ARS inhibitors. DESIGN, SETTING, AND PARTICIPANTS: From 41 mCRPC patients, CTCs were prospectively enriched using AdnaTest platform and analyzed for AR-V7 with and without the highly sensitive assay. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The first objective of the study was to compare AR-V7 detection rates with and without the highly sensitive assay. Next, we investigated how AR-V7 (detected without the highly sensitive assay) and hsAR-V7 status influenced prostate-specific antigen (PSA) response and long-term clinical outcomes (PSA progression-free survival [PFS] and radiological PFS) after ARS-inhibitor treatment. Finally, discriminatory abilities of the assays were assessed by C-index to compare their impact on long-term clinical outcomes. RESULTS AND LIMITATIONS: AR-V7 detection rates increased from 22% to 56% when the highly sensitive assay was used. The discriminatory abilities of hsAR-V7 for PSA PFS (C-index, 0.74; 95% confidence interval [CI], 0.60-0.88) and radiological PFS (0.70; 95% CI, 0.55-0.85) were higher than those of AR-V7 detected without the highly sensitive assay (0.60, 0.51-0.72, and 0.56, 0.44-0.67, respectively). After ARS-inhibitor treatment, PSA response was lower in hsAR-V7+ (53%) than in hsAR-V7- (93%) patients (p = 0.016). AR-V7+ patients had shorter median PSA PFS (3.0 vs 10.6 mo, p = 0.032) and nonsignificantly shorter median radiological PFS (6.0 vs 14.8 mo, p = 0.24) compared with AR-V7- patients. The hsAR-V7+ status was associated with shorter median PSA PFS (3.0 mo vs not reached, p = 0.0001) and radiological PFS (median, 6.0 mo vs not reached, p = 0.0026). CONCLUSIONS: The hsAR-V7 assay achieved the highest AR-V7 detection rates among those reported in mCRPC. Discriminatory abilities for long-term clinical outcomes were better with hsAR-V7 assay. PATIENT SUMMARY: We prospectively analyzed circulating tumor cells from men with metastatic castration-resistant prostate cancer for androgen receptor splice variant 7 (AR-V7) status using a highly sensitive assay. It yielded higher AR-V7 detection rates and predicted resistance to androgen receptor signaling inhibitors with better discriminatory abilities for long-term clinical outcomes.
引用
- Maillet D, Allioli N, Peron J, et al. Improved Androgen Receptor Splice Variant 7 Detection Using a Highly Sensitive Assay to Predict Resistance to Abiraterone or Enzalutamide in Metastatic Prostate Cancer Patients. Eur Urol Oncol. 2019. PMID: 31676281. doi:10.1016/j.euo.2019.08.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。